三星C&T二季度利润大增但股价因贸易业务放缓担忧下跌

Iran fires missiles at U.S. forces in Middle East, ending ceasefire lull
Introduction & Market Context
Samsung C&T presented second-quarter 2026 earnings results on July 29 that showed robust profit growth and margin expansion across most business segments, yet shares fell 5.8% to KRW 177,000 as investors weighed concerns about near-term headwinds in the trading business and the sustainability of the construction boom.
The South Korean conglomerate reported consolidated sales of KRW 11,995 billion and operating profit of KRW 1,032 billion for the quarter, representing increases of 14.6% and 43.3% respectively from the prior quarter. The operating margin expanded to 8.6%, up 1.7 percentage points sequentially, driven primarily by the ramp-up of semiconductor fabrication plant construction and improved performance in the biologics division.
Despite the strong quarterly performance, the stock decline reflected market caution about management’s guidance that trading and investment earnings would moderate in the third quarter due to softer commodity markets and European Union steel import quotas.
Quarterly Performance Highlights
The company’s consolidated financial results for the second quarter demonstrated broad-based strength across its diversified business portfolio. As shown in the following detailed breakdown of quarterly and year-over-year performance:
Sales growth was particularly robust on a year-over-year basis, rising 19.7% from KRW 10,022 billion in the second quarter of 2025. Operating profit jumped 37.1% year-over-year from KRW 753 billion, reflecting improved operational efficiency and favorable project mix.
The company’s six major business segments showed varied performance. Engineering & Construction generated sales of KRW 3,988 billion with operating profit of KRW 202 billion, achieving a 5.1% margin that marked a significant improvement from the 3.2% margin in the first quarter. Trading & Investment posted sales of KRW 4,703 billion with operating profit of KRW 142 billion. The Bio segment, which includes Samsung Biologics and Samsung Epis Holdings, contributed sales of KRW 1,619 billion and operating profit of KRW 586 billion, maintaining a strong 36.2% operating margin.
Net profit for the quarter reached KRW 916 billion, though this declined from KRW 1,086 billion in the prior quarter due to a significant decrease in non-operating profit, which fell to negative KRW 11 billion from positive KRW 526 billion in the first quarter.
Engineering & Construction Momentum
The Engineering & Construction division emerged as a key driver of the quarter’s performance, with management highlighting the acceleration of Hi-Tech semiconductor fabrication plant projects as the primary catalyst. According to CFO Byung-Ho Kang, the division is benefiting from "the global semiconductor super cycle driven by AI demand" as clients make "unprecedented levels of fab investments."
The following chart illustrates the division’s performance trajectory and new order activity:
New orders in the second quarter totaled KRW 5,448 billion, bringing the first-half total to KRW 10,448 billion and pushing the backlog to KRW 34,244 billion. Major projects secured during the quarter included the Anyang Stadium Redevelopment (KRW 0.8 trillion), Daechi Ssangyong 1st (KRW 0.7 trillion), China Xi’an FAB (KRW 0.5 trillion), and the National AI Computing Center (KRW 0.5 trillion).
Notably, the company secured KRW 4.0 trillion in housing construction rights during the second quarter, including high-profile projects such as Apgujeong District 4 (KRW 2.1 trillion) and Gaepo Woosung 4th (KRW 0.8 trillion). This brought the cumulative housing construction rights to significant levels, though still below the peak of KRW 5.5 trillion secured in 2025.
Management indicated that Hi-Tech orders for the full year are expected to "significantly exceed" the original target of KRW 6.8 trillion, with the company reviewing an upward revision to guidance. The outlook for the third quarter anticipates continued sales and operating profit growth as High-Tech project construction gains momentum, with particular acceleration expected in the second half.
Trading & Investment Mixed Signals
The Trading & Investment segment delivered strong second-quarter results but faces near-term headwinds that contributed to investor caution. The division’s performance and key commodity trends are detailed in the following presentation:
Sales of KRW 4,703 billion represented a 14.3% increase from the prior quarter and a 24.6% jump year-over-year. Operating profit of KRW 142 billion yielded a 3.0% margin, up from 2.7% in the first quarter. Management attributed the improvement to timely responses to rising chemical and fertilizer prices, increased sales of high-margin steel products, and favorable nickel price movements.
Commodity price trends showed significant year-over-year increases, with urea up 70.8% to USD 668 per metric ton, copper up 40.0% to USD 13,326, and nickel up 19.7% to USD 18,165. However, management cautioned that third-quarter earnings are expected to moderate due to lower volumes from deteriorating market conditions and EU steel import quotas.
The Solar PV development business continued to expand its pipeline, reaching 32 gigawatts in the first half of 2026. The division generated disposal gains of USD 22.2 million in the second quarter, with management targeting a pipeline of approximately 20 gigawatts for the full year. The solar business represents a strategic growth area as the company positions itself to capture opportunities in renewable energy infrastructure.
Consumer-Facing Businesses Show Resilience
Samsung C&T’s consumer-focused segments demonstrated mixed but generally improving performance during the quarter. The following breakdown shows results for the Fashion and Leisure divisions:
The Fashion segment posted sales of KRW 593 billion with operating profit of KRW 54 billion, achieving a 9.1% margin that represented a 2.5 percentage point improvement from the prior quarter. Management attributed the growth to improving consumer sentiment and strong performance from core and newly launched brands, with enhanced discount management driving profitability gains.
The Leisure division, which includes the Everland theme park and Caribbean Bay water park, showed sequential improvement but remained challenged year-over-year. Sales of KRW 206 billion nearly doubled from the first quarter’s seasonally weak KRW 105 billion, while operating profit reached break-even compared to a KRW 35 billion loss in the prior quarter. However, the division faced headwinds from dispersed leisure demand and the completion of a large-scale landscape project. Management indicated plans to strengthen Caribbean Bay’s competitiveness and capture peak-season demand through seasonal content offerings.
Bio Business Expansion and Strategic Acquisition
The Bio segment, comprising Samsung Biologics and Samsung Epis Holdings, continued to serve as a major profit contributor while the company announced a significant strategic acquisition to expand its capabilities. Performance metrics and outlook are presented in the following detail:
Samsung Biologics generated sales of KRW 1,226 billion with operating profit of KRW 580 billion, achieving a remarkable 47.3% operating margin. The year-over-year growth was driven by full-capacity operation of Plants 1 through 4 and favorable foreign exchange effects. Samsung Epis Holdings contributed sales of KRW 393 billion with operating profit of KRW 6 billion, though earnings declined year-over-year due to changes in product supply timing.
The Food & Beverage division, operated through wholly-owned subsidiary Welstory, posted sales of KRW 886 billion with operating profit of KRW 48 billion, representing a 5.4% margin. The improvement was attributed to increased meal volumes from newly secured food service operations and growth in the food distribution business.
In a major strategic move, Samsung Biologics announced plans to acquire Swiss PolyPeptide for approximately KRW 2.7 trillion. The acquisition aims to expand the company’s contract development and manufacturing organization (CDMO) business portfolio by securing capabilities in the rapidly growing peptide sector, particularly for obesity and diabetes treatments. The deal also provides manufacturing facilities and a base in Europe, complementing existing U.S. operations.
Management projected that Samsung Biologics would achieve annual sales growth of 15-20% year-over-year through gradual ramp-up of Plant 5 and the Rockville Campus in the United States, with profitability expected to remain at prior-year levels. Samsung Epis Holdings is targeting annual sales growth exceeding 10% on expanded biosimilar sales, though profitability may be constrained by development costs for follow-on biosimilars and new drugs.
Strategic Growth Initiatives
Samsung C&T outlined an ambitious roadmap for future growth centered on energy infrastructure, data centers, and life sciences investments. The comprehensive strategy is detailed in the following presentation:
In the energy sector, the company is pursuing diversification across multiple technologies to address rising global energy demand. The power and LNG business will continue participation in existing markets while expanding into Southeast Asia and Europe. The solar photovoltaic and battery energy storage system (BESS) business plans expansion in southwestern Korea, Australia, and North America through large-scale EPC execution and partnership-based equity investments.
Nuclear power represents a particularly significant opportunity, with the company adopting multiple technology models including APR1400, AP1000, and CANDU under South Korea’s Team Korea initiative. Key projects include Vietnam’s NPP Unit 2, where Team Korea’s construction contractor selection is expected in 2027 with targeted commercial operation in 2035, and Romania’s Units 3&4, where the company is pursuing contractor participation in collaboration with Korea Hydro & Nuclear Power.
The small modular reactor (SMR) initiative targets projects totaling 12.2 gigawatts, centered on five European countries. This includes 11.7 gigawatts through partnership with GVH in Sweden, Poland, Estonia, and Finland, plus 0.5 gigawatts through collaboration with NuScale on Romania’s first-of-a-kind unit.
For data centers, Samsung C&T is strengthening competitiveness by diversifying business models to include modular data centers and integrated data center-plus-power generation solutions. The company is pursuing follow-on orders linked to global cloud service providers while promoting additional orders in Korea and Southeast Asia, with a target exceeding KRW 2 trillion in 2026 orders.
In life sciences, the company announced plans to establish Life Science Fund III with KRW 200 billion in capital, including KRW 79.2 billion from Samsung C&T. This would bring cumulative fund commitments to KRW 442 billion, supporting strategic partnerships with global companies developing next-generation innovative technologies. Recent investments include Cartography Biosciences, a U.S.-based company with an antigen target and drug discovery platform based on genomic data and artificial intelligence technology.
Financial Position and Outlook
Samsung C&T’s balance sheet remained strong during the quarter, with significant improvements in leverage metrics and cash position. The consolidated statement of financial position shows the following key metrics:
Total assets increased to KRW 163,769 billion, up KRW 58,682 billion from the prior quarter, primarily due to growth in non-current assets. Total equity rose to KRW 113,709 billion, with controlling equity reaching KRW 105,553 billion. Total debt declined to KRW 3,087 billion from KRW 3,981 billion in the first quarter, resulting in a debt-to-equity ratio of 44%, down from 50% sequentially.
The company’s net cash position improved substantially to KRW 4,683 billion from KRW 2,714 billion in the prior quarter, reflecting strong operational cash generation and reduced borrowings. Cash and cash equivalents plus short-term financial instruments totaled KRW 7,770 billion.
Cash flow performance demonstrated robust operational strength, as illustrated in the following statement:
Cash flows from operating activities totaled KRW 2,506 billion in the second quarter, up from KRW 1,147 billion in the first quarter. For the first half, operating cash flow reached KRW 3,653 billion. Investing activities consumed KRW 966 billion during the quarter, while financing activities resulted in a cash outflow of KRW 1,320 billion, primarily due to debt repayment of KRW 899 billion.
Management indicated that full-year 2026 revenue and operating profit are expected to exceed original guidance, supported by continued strength in Hi-Tech construction and other project work. However, the company acknowledged that trading business earnings may face pressure in the third quarter before recovering later in the year.
The shareholder return policy for 2026-2028 calls for redistributing 60-70% of affiliate dividend income, though the current policy does not include share buybacks or cancellations. The company has maintained dividend payments for 11 consecutive years, supported by its strong cash position and diversified earnings base.
While the stock’s 5.8% decline following the earnings presentation suggests investor caution about near-term volatility in certain business segments, the company’s diversified portfolio, strong balance sheet, and positioning in growth markets such as semiconductor fabrication, nuclear power, and biologics manufacturing provide multiple pathways for sustained long-term growth.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.